E. Ohman J or Asset Management AB Acquires 450 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

E. Ohman J or Asset Management AB increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,750 shares of the company’s stock after acquiring an additional 450 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in IDEXX Laboratories were worth $1,550,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the third quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth approximately $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on IDXX shares. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $524.38.

IDEXX Laboratories Stock Down 0.9 %

IDXX stock opened at $465.03 on Wednesday. The stock has a market cap of $38.08 billion, a P/E ratio of 44.84, a P/E/G ratio of 3.64 and a beta of 1.37. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The stock’s fifty day simple moving average is $424.92 and its two-hundred day simple moving average is $453.54. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.